About Us

Company Overview

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets.  Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 420-person salesforce to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform.  Our pharmaceutical business features Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation approved by FDA and pending launch by partner Tesaro, IV formulation in Phase 3).  Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a).  We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy.

OPKO continues to explore acquisition opportunities for complementary pharmaceuticals, compounds, technologies, and businesses. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and pursuit of complementary and strategic acquisitions and investments.




Strategic Investments

  • EirGen Pharma
    Acquired: (May 2015)
  • OPKO Chile
    Acquired: Pharma Genexx (October 2009) Acquired: ALS Distribuidora Limitada (April 2012)
    Acquired: Farmadiet (August 2012)
  • OPKO FineTech
    Acquired: (December 2011)
  • OPKO Mexico
    Acquired: Pharma Exakta (February 2010)


  • Bio-Reference Laboratories Acquired: (August 2015)
  • OURLabs Acquired: (December 2012)
  • OPKO Diagnostics Acquired: Claros Diagnostics (October 2011)
  • Molecular Diagnostics


  • OPKO Biologics Acquired: PROLOR (August 2013)
  • OPKO Renal Acquired: Cytochroma, Inc (March 2013)
  • OPKO CURNA Acquired: (February 2011)
  • ARNO Therapeutics
  • ChromaDex Corporation.
  • Cocrystal Pharma
  • Neovasc, Inc.
  • Pharmsynthez
  • RXi Pharmaceuticals
  • SciVac Therapeutics Inc.
  • Sevion
  • Zebra Biologics

Experienced Management Team:

OPKO has a highly experienced management team that we believe has demonstrated an ability to successfully build and manage pharmaceutical businesses. Our Chairman and Chief Executive Officer, Dr. Phillip Frost, founded and served as Chairman and Chief Executive Officer of IVAX Corporation, a multi-national pharmaceutical company, from 1987 until the acquisition of IVAX by Teva Pharmaceutical Industries, Limited in January 2006. Dr. Frost currently serves as Chairman of the Board of Teva. Prior to Ivax, Dr. Frost founded and served as Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986. Our other senior executive officers are also veterans in the pharmaceutical industry and have extensive development, regulatory, and commercialization expertise.

It is our conviction that OPKO’s experienced management team has the development, regulatory, and commercialization expertise and relationships able to access and facilitate excellent commercial opportunities.